CDK7 and head and neck squamous cell carcinoma: The therapeutic potential of CDK7 inhibitors was also tested in already formed HNSCC PDOs, which offer a physiologically relevant patient-derived model that mimics the architectural and genetic heterogeneity of the primary tumors of origin.